Alector

Alector company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are a late-stage clinical biotechnology company with a mission to make degenerative brain disorders history. Our robust portfolio of therapies is focused on counteracting the devastating progression of neurodegenerative diseases, particularly in areas of high unmet need where therapeutic options are limited. We are at the forefront of a scientific and clinical revolution, committed to understanding the complex mechanisms that drive neurodegenerative diseases, including the roles of toxic misfolded proteins, deficient proteins, and lysosomal, immune system, and neuronal dysfunction. We aim to develop product candidates that remove toxic proteins, replace critical deficient proteins, and restore immune and nerve cells to normal function. To pursue this aim, we are advancing a portfolio of programs that address genetically validated targets. These programs leverage our deep understanding of the genetic underpinnings of these diseases, combined with our expertise in drug development, proprietary protein engineering, antibody discovery, and our innovative Alector Brain Carrier (ABC) technology for blood-brain barrier (BBB) transport. We are advancing ABC, our proprietary, versatile BBB technology platform and selectively applying it within our portfolio. Alector is based in South San Francisco, CA. We were founded in 2013 by thought leaders in biotechnology, neuroscience, and antibody drug discovery.

Company Details

Employees
223
Founded
-
Address
131 Oyster Point Blvd,
Phone
(415) 231-5660
Email
in****@****tor.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
South San Francisco, California
Looking for a particular Alector employee's phone or email?

Alector Questions

News

Alector Announces Topline Results from Latozinemab Phase 3 - GlobeNewswire

Alector Announces Topline Results from Latozinemab Phase 3 GlobeNewswire

Alector Provides Executive Leadership Update - Yahoo Finance

Alector Provides Executive Leadership Update Yahoo Finance

Late-Stage Neurodegeneration Pipeline: Alector Reveals Phase 3 FTD Drug and Brain Carrier Breakthroughs - Stock Titan

Late-Stage Neurodegeneration Pipeline: Alector Reveals Phase 3 FTD Drug and Brain Carrier Breakthroughs Stock Titan

Alector, Inc. to Host Conference Call for Q2 2025 Results and Mid-Year Business Update - Quiver Quantitative

Alector, Inc. to Host Conference Call for Q2 2025 Results and Mid-Year Business Update Quiver Quantitative

Alector Completes Enrollment for Phase II Trial of Investigational Alzheimer’s Disease Therapy - Applied Clinical Trials

Alector Completes Enrollment for Phase II Trial of Investigational Alzheimer’s Disease Therapy Applied Clinical Trials

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease - Yahoo Finance

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease Yahoo Finance

Neurodegenerative Disease Pioneer Alector Sets Major Investor Conference Schedule for September 2025 - Stock Titan

Neurodegenerative Disease Pioneer Alector Sets Major Investor Conference Schedule for September 2025 Stock Titan

Alector, Inc. Reports Q4 2024 Financial Results and Provides Updates on Clinical Trials and Pipeline Development - Quiver Quantitative

Alector, Inc. Reports Q4 2024 Financial Results and Provides Updates on Clinical Trials and Pipeline Development Quiver Quantitative

Alector to Participate in Upcoming Healthcare Conferences - GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences GlobeNewswire

Alector, Inc. Advances Neurodegeneration Pipeline with Key Clinical Trials and Strong Financial Position for 2025 - Quiver Quantitative

Alector, Inc. Advances Neurodegeneration Pipeline with Key Clinical Trials and Strong Financial Position for 2025 Quiver Quantitative

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs - GlobeNewswire

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs GlobeNewswire

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update - Yahoo Finance

Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update Yahoo Finance

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Alector Reports Second Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital - Yahoo Finance

Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital Yahoo Finance

Alector, Inc. Secures Up to $50 Million Debt Financing Agreement with Hercules Capital - Quiver Quantitative

Alector, Inc. Secures Up to $50 Million Debt Financing Agreement with Hercules Capital Quiver Quantitative

Alector Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

Alector Reports First Quarter 2025 Financial Results and Provides Business Update GlobeNewswire

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) - Yahoo Finance

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024) Yahoo Finance

Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease - Yahoo Finance

Alector Announces Completion of Enrollment in the INVOKE-2 Phase 2 Clinical Trial of AL002, a TREM2 Monoclonal Antibody, in Individuals With Early Alzheimer’s Disease Yahoo Finance

Alector to Host Virtual Research and Development Event - GlobeNewswire

Alector to Host Virtual Research and Development Event GlobeNewswire

Alector Presents 12-Month Results from the INFRONT-2 Phase - GlobeNewswire

Alector Presents 12-Month Results from the INFRONT-2 Phase GlobeNewswire

Alector Provides Executive Leadership Update - GlobeNewswire

Alector Provides Executive Leadership Update GlobeNewswire

Alector and GSK announce global collaboration in - GlobeNewswire

Alector and GSK announce global collaboration in GlobeNewswire

Alector Announces Departure of Chief Business Officer - GlobeNewswire

Alector Announces Departure of Chief Business Officer GlobeNewswire

Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update - GlobeNewswire

Alector Reports 2020 Fourth Quarter and Full Year Financial Results and Provides Business Update GlobeNewswire

Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients - GlobeNewswire

Alector Announces Initiation of Phase 1b Study of AL003 in Alzheimer’s Disease Patients GlobeNewswire

Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - FinancialContent

Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference FinancialContent

Top Alector Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant